Drug intelligence / Profile preview

quinine topical nasal spray

Development stage: Phase 2
Lead developer: GeneOne Life Science
Modality: Small Molecules
Administration: Intranasal, Topical

Overview

GLS-1200 is a topical nasal spray containing quinine being developed by GeneOne Life Science. It functions as a Taste 2 receptors agonist. The drug has been investigated for multiple indications including the prevention of SARS-CoV-2 infection (COVID-19) and sinusitis after endoscopic sinus surgery. It is administered intranasally as a spray.

Targets

TAS2R10 (Taste receptor type 2 member 10)TAS2R4 (Taste receptor type 2 member 4)

Beyond the preview

Go deeper on quinine topical nasal spray.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on quinine topical nasal spray.

Explore the full profile